Ziprasidone Capsule Suppliers & Bulk Manufacturers
Available Forms: Oral Capsules
Available Strengths: 20 mg, 40 mg, 60 mg, 80 mg
Reference Brands: Zeldox®(EU); Geodon®(US)
Category:
Antipsychotropic Drugs
Ziprasidone is an atypical antipsychotic that works by blocking dopamine D2 and serotonin 5-HT2A receptors, helping to normalize neurotransmission in the brain. It also inhibits serotonin and norepinephrine reuptake, contributing to mood stabilization. Ziprasidone capsules are used to treat schizophrenia and bipolar I disorder (acute manic or mixed episodes) in adults.
Ziprasidone Capsule is available in Oral Capsules
and strengths such as 20 mg, 40 mg, 60 mg, 80 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Ziprasidone Capsule is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Ziprasidone Capsule can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Ziprasidone capsules (brand name: Geodon in the U.S., Zeldox in the EU) are FDA-approved in the United States and EMA-authorized in the European Union for the treatment of schizophrenia and bipolar I disorder (acute manic or mixed episodes) in adults. Regulatory compliance requires GMP-certified oral solid dosage manufacturing, bioequivalence data for generics, and long-term safety and efficacy studies. U.S. labeling includes a boxed warning for increased mortality in elderly patients with dementia-related psychosis. EU marketing authorizations mandate Risk Management Plans (RMPs) and continuous pharmacovigilance. For dossier-ready Ziprasidone capsules, visit Pharmatradz.com.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing